Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 8:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,279 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infection Prophylaxis Clear all

Conditions: HIV Prevention, HIV Infections
Interventions: Tenofovir, HEC Placebo, Open label tenofovir tablet; Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Los Angeles, California • Pittsburgh, Pennsylvania

Conditions: HIV Infections, Sexually Transmitted Diseases, Stigma, Social
Interventions: Information Resources, Social Support, HIV Testing; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 15 Years to 29 Years · Male only
Enrollment: 750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Chapel Hill, North Carolina • Durham, North Carolina • Philadelphia, Pennsylvania

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Rifabutin; Drug
Lead sponsor: Pharmacia; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 31
States / cities: Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 22 more

Conditions: Influenza, Healthy
Interventions: Bivalent influenza vaccine, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Stockbridge, Georgia • Portland, Oregon

Conditions: Malaria
Interventions: BNT165c, BNT165d, Placebo; Biological · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 163 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 5
States / cities: Tempe, Arizona • Baltimore, Maryland • Las Vegas, Nevada + 2 more

Conditions: Chronic Obstructive Pulmonary Disease, Lung Non-Small Cell Carcinoma, Pneumonia, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
Interventions: Quality-of-Life Assessment, Questionnaire Administration, Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine; Other · Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 50 Years to 79 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: HIV Infections, Sinusitis
Interventions: Pseudoephedrine hydrochloride, Guaifenesin, Cefuroxime axetil, Beclomethasone dipropionate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 10
States / cities: San Diego, California • San Francisco, California • The Bronx, New York + 1 more

Conditions: MRSA - Methicillin Resistant Staphylococcus Aureus Infection
Interventions: Antibiotic Prophylaxis; Drug
Lead sponsor: CAMC Health System; Other
Eligibility: 18 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Charleston, West Virginia

Conditions: HIV, Sexual Risk, Sexually Transmitted Diseases, Substance Abuse, Violence, Victimization
Interventions: Test, Treat, Retain(TTR) + Women's Health CoOp (WHC), Test, Treat, Retain(TTR) only; Behavioral · Biological
Lead sponsor: RTI International; Other
Eligibility: 15 Years to 55 Years · Female only
Enrollment: 641 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: COVID-19, Coronavirus Infection, Sars-CoV2, Corona Virus Infection, COVID, Coronavirus, Coronavirus-19, Coronavirus 19
Interventions: Hydroxychloroquine, Vitamin C, Vitamin D, Zinc; Drug · Dietary Supplement
Lead sponsor: ProgenaBiome; Other
Eligibility: 18 Years and older
Enrollment: 254 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Ventura, California

Conditions: HIV
Interventions: Observational; Other
Lead sponsor: HIV Prevention Trials Network; Network
Eligibility: 18 Years and older · Male only
Enrollment: 226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Chapel Hill, North Carolina

Conditions: COVID-19
Interventions: Tocilizumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV/AIDS
Interventions: PHAT Life: Preventing HIV/AIDS Among Teens--PS Arm, PHAT Life: Preventing HIV/AIDS Among Teens--YR Arm; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 13 Years to 17 Years
Enrollment: 218 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Ebola Hemorrhagic Fever
Interventions: Placebo, AVI-6002; Drug
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: HIV-1-infection, Coronary Microvascular Dysfunction, Metabolic Disease
Interventions: Health Education, Subspecialty clinic referral; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 45 Years to 75 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dengue Fever
Interventions: rDEN3delta30/31-7164; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: Affect Management, General Health Promotion; Behavioral
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 13 Years to 18 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Vulvar Diseases, HPV Infection, Vulvar HSIL, Pre-Cancerous Dysplasia, HPV Disease, VIN, Usual Type, VIN 2 of Usual Type, VIN 3 of Usual Type, Vin II, Vin III, VIN Grade 2, VIN Grade 3, High Grade Intraepithelial Neoplasia
Interventions: Artesunate ointment, Placebo ointment; Drug
Lead sponsor: Frantz Viral Therapeutics, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Fort Myers, Florida • Indianapolis, Indiana • Cleveland, Ohio + 1 more

Conditions: Zika Virus, Zika Virus Infection
Interventions: VLA1601, Placebo; Biological
Lead sponsor: Valneva Austria GmbH; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Contraception, Prevention of Sexually Transmitted Infections
Interventions: Control Latex Condom C, Polyurethane Condom A, Polyurethane Condom B; Device
Lead sponsor: Sagami Rubber Industries Co., Ltd.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Endophthalmitis
Interventions: Moxifloxacin, Placebo; Drug
Lead sponsor: Jason Ahee, M.D.; Industry
Eligibility: 40 Years and older
Enrollment: 60,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: St. George, Utah

Conditions: Hepatitis C, Depression
Interventions: Citalopram or Placebo; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Urinary Tract Infection (Diagnosis)
Interventions: Methenamine Hippurate 1g BD, Antibiotic prophylaxis; Drug · Other
Lead sponsor: Atlantic Health System; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 190 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Morristown, New Jersey

Conditions: Dengue
Interventions: rDEN3/4delta30(ME), Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet

Increasing Engagement and Improving HIV Outcomes Via HealthMPowerment

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

D2560C00015 FluMist Annual Safety Study 2018

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence

Preventing Frequent Sinus Infections in HIV-Infected Patients

Vascular Surgical Antibiotic Prophylaxis Study (VSAPS 2)

WHC+ (Women's Health CoOp PLUS)

A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection

HPTN 073 Black Men Who Have Sex With Men (MSM) Pre-Exposure Prophylaxis (PrEP)

Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection

PHAT Life: Peer Versus Adult-Led HIV Prevention for Juvenile Offenders

Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus

Improving Coronary Vascular Health in Women

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy Adults

An Affect Management Intervention for Juvenile Offenders

Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)

Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults

Evaluation of Polyurethane Male Condoms

Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery

VISN 20: Prophylactic Treatment of Interferon-Induced Depression in Hepatitis C Patients

Is Methenamine Prophylaxis for Urinary Tract Infection After Midurethral Sling as Effective as Antibiotic Prophylaxis?

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults